Actithera

News

A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.

News

Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.